CoChat
Sign Up
Cited by 17Extracellular vesicles in diseaseBiomedical Ethics and RegulationCAR-T cell therapy research

Isolator-based point-of-care manufacturing: a practical solution for GMP-compliant cell and extracellular vesicles therapy production

Open access
Chiu, Yu-Sung, Wang, Kun-Liang, Wu, Kun-Lieh·2025·Frontiers in Bioengineering and Biotechnology
DOI 10.3389/fbioe.2025.1644318PMC PMC12440961
Open this paper in CoChat — free accountOpen PDF

Abstract

Cell and extracellular vesicle (EV)-based therapies represent a promising frontier in regenerative medicine and immunotherapy. However, their clinical translation is often constrained by the complexities of Good Manufacturing Practice (GMP)-compliant production, particularly under centralized manufacturing models. This Perspective discusses the emerging role of decentralized, point-of-care (POC) manufacturing in enabling timely, scalable, and patient-specific delivery of cell and EV therapeutics, with a focus on isolator-based systems as core manufacturing infrastructure. We discuss current advances in closed-system technologies, regulatory frameworks, and quality control (QC) strategies supporting GMP compliance in decentralized environments. Real-world applications and case studies illustrate feasibility and translational impact. Isolator-based platforms offer modular, sterile, automation-compatible environments that support both autologous and selected allogeneic product manufacturing at clinical sites. These systems reduce contamination risks, lower facility requirements, and enable integration with real-time QC testing. Despite these advantages, challenges remain, including regulatory ambiguity, workforce training limitations, and quality assurance gaps in decentralized settings. Emerging solutions include automated closed-system bioreactors, digitalized QC workflows, and harmonized operational standards to ensure product safety and consistency. Strategic coordination among regulators, hospitals, and developers will be essential to overcome operational and compliance hurdles. With appropriate infrastructure, skilled personnel, and standardized processes in place, isolator-based POC manufacturing holds the potential to transform how advanced therapies are produced and delivered—ultimately enhancing patient access to safe, effective, and personalized cell and EV-based treatments.

AI snapshot

Written from the paper’s full text.

TL;DR

This Perspective argues that isolator-based, closed-system point-of-care (POC) manufacturing can make GMP-compliant production of cell and extracellular vesicle (EV) therapies feasible within hospitals, reducing contamination risk, facility requirements, and vein-to-vein time. It surveys the enabling technology, QC/regulatory frameworks, and remaining barriers (regulatory ambiguity, workforce training, QA gaps, cost) without presenting new primary data.

Key findings

  • Isolators are fully sealed systems that can operate in lower-grade backgrounds (Grade D, ISO 8, ~20 ACH) than BSCs or RABS, which require Grade B cleanrooms (ISO 5 at rest, ISO 7 in operation, ≥240–300 ACH), while providing automated, quantifiable decontamination and validated leak control (Table 1).
  • Rapid QC can shorten release timelines: automated fluorescence-based microbial detection (e.g., BacT/Alert) gives sterility results in 3–5 days versus the compendial 14 days, solid-phase cytometry (e.g., ScanRDI) in under 3 h, and qPCR mycoplasma testing in 1–4 h.
  • POC manufacturing is best suited to autologous, non-genetically modified, short-shelf-life products (e.g., chondrocytes, BMSCs, ADSCs, CIK cells, DCs), while centralized manufacturing remains dominant for allogeneic off-the-shelf products; isolators can nonetheless support gene-modified therapies by containing transduction and expansion steps.
  • Cited examples of feasibility include isolator-based IVF improving blastocyst development and pregnancy/implantation rates, the authors' own GMP isolator-produced WJ-MSC exosomes showing neuroprotection in a rodent stroke model, and the "Tissue Factory" producing myoblast sheets, chondrocytes, and iPSCs without microbial contamination.

Methods

Not stated in the paper (this is a Perspective article, not a primary study). The text synthesizes published literature, regulatory guidance (PIC/S, ISO, USP, ISEV MISEV2018), and illustrative case studies to argue for isolator-based decentralized manufacturing; no systematic search strategy, dataset, or quantitative analysis is described. QC parameters discussed include immunophenotyping panels (e.g., CD3/CD56 for CIK, CD56+CD3− for NK, CD105/CD73/CD90 for MSCs per ISCT criteria), potency assays (chromium-51 release, flow-based killing, luminescence), and EV characterization (30–150 nm size, tetraspanins CD63/CD81/CD9, cargo analysis).

Limitations

The paper itself states that regulatory classification of cell therapies (procedure vs. ATMP) remains ambiguous, that workforce availability and technical expertise are limited especially at smaller centers, that decentralized sites may lack full GMP QA systems, and that isolator capital costs, spatial requirements, and maintenance constrain scalability; automation and robotic platforms remain costly and not widely adopted. Evident from the text: as a Perspective it presents no primary data, no systematic review methodology, and no quantitative comparison of POC versus centralized outcomes; several supporting examples are drawn from the authors' own prior work and from non-cell-therapy contexts (IVF).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fbioe.2025.1644318

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

28 of 55 cited sources checked · 7 supported · 0 flagged · accuracy not yet measured

  • Interpretationcitation

    Automated isolator-based platforms represent a paradigm shift towards scalable, cost-effective, and standardized production of cell-based healthcare products.

    “Such automated isolator-based platforms represent a paradigm shift towards scalable, cost-effective, and standardized production of cell-based healthcare products (Kikuchi et al., 2018).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Kikuchi et al., 2018 source

      The Conclusion and Discussion (‘Modularity, flexibility and cost-effectiveness’; page not provided) describe a novel automated isolator-based platform expected to lower costs, improve quality consistency, and support multiple batches. But these are largely projected benefits, and parallel production is conditional on resolving regulatory issues; the paper does not establish scalable, cost-effective, standardized production as an achieved paradigm shift. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • Premisecitation

    In some jurisdictions, the hospital exemption pathway allows non-commercial use of ATMPs within the same institution under defined conditions, facilitating certain POC manufacturing models.

    “In some jurisdictions, the “hospital exemption” pathway allows for non-commercial use of ATMPs within the same institution under defined conditions, facilitating certain POC manufacturing models (Sánchez-Guijo et al., 2023).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Sánchez-Guijo et al., 2023 source

      The Hospital Exemption section (page unavailable) describes non-routine ATMP manufacture outside the standard marketing-authorization pathway, subject to quality standards, national authorization, and use in a hospital within the same Member State. It also describes academic manufacturing, but does not require manufacture and use within the same institution or explicitly link the exemption to point-of-care manufacturing models. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
  • Premisecitation

    Gene-modified therapies, including iPSC-derived products and CAR-T cells, present distinct biosafety and technical challenges for POC implementation.

    “Gene-modified therapies, including iPSC-derived products and CAR-T cells, present distinct biosafety and technical challenges for POC implementation (Nakagawa et al., 2014; Moradi et al., 2023).”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites Nakagawa et al., 2014 source

      The Discussion says hiPSC clinical use requires attention to quality, safety, GMP manufacturing, and animal-derived materials; the Abstract also describes technical problems with conventional culture. Our copy does not address CAR-T cells or challenges specific to point-of-care (POC) implementation. Its CPC refers to a Cell Processing Center, not point-of-care delivery. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites Moradi et al., 2023 source
  • Premisecitation

    Integrating robotic arms within isolator systems represents a promising hybrid approach, enabling high-throughput, GMP-compliant cell manufacturing in compact, modular setups.

    “Integrating robotic arms within isolator systems represents a promising hybrid approach, enabling high-throughput, GMP-compliant cell manufacturing in compact, modular setups (Melocchi et al., 2024; Ochs et al., 2022).”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites Melocchi et al., 2024 source

      The Robotic Cluster Design section describes a robotic arm surrounded by task-specific modules, and the Discussion says the system could support parallel processing and scale-up in a small footprint. But the paper does not describe integrating the arm within an isolator or establish GMP compliance; the Sterility of Robotic Processing section reports a proof-of-concept test in a standard, non-cleanroom laboratory. (LLM, conf=0.89)

      Experimental — accuracy not yet measured
    • cites Ochs et al., 2022 source

      The Results (AUTOSTEM platform overview and Sterility; page not provided) describe robot arms in a grade A isolator, and the Discussion describes 24/7 production and GMP-oriented design. The Introduction discusses modular processing components, but the copy does not establish that this particular setup is compact or demonstrate high-throughput, GMP-compliant manufacture; it calls the platform GMP-amenable and says cleaning validation will be performed. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
  • Premisecitation

    Automated fluorescence-based microbial detection systems such as BacT/Alert detect metabolic activity or CO2 production of microorganisms in culture bottles, providing results within 3-5 days rather than 14 days.

    “For example, automated fluorescence-based microbial detection systems, such as BacT/Alert, detect metabolic activity or CO2 production of microorganisms in culture bottles, providing results within 3–5 days rather than 14 days (Lim et al., 2014; Bugno et al., 2015).”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites Lim et al., 2014 source
    • cites Bugno et al., 2015 source

      The Introduction describes BacT/ALERT 3D as an automated system that detects microbial growth through biochemical or physiological changes, including CO2 production measured colorimetrically—not by fluorescence. The Results and Discussion report faster detection than conventional testing, but do not establish a 3–5-day result time; the Incubation conditions section says both methods were incubated for 14 days. Page numbers are unavailable in our copy. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
  • Classified as probably not a substantial claim. 14
  • May combine two claims. 32

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Sterility assurance, process consistency, and batch reproducibility are essential to ensure product safety and efficacy.

    “Key factors such as sterility assurance, process consistency, and batch reproducibility are essential to ensure product safety and efficacy (Stroncek et al., 2010).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Stroncek et al., 2010 source

  • May combine two claims.

    Premisecitation

    Non-genetically modified cell therapies and their derived extracellular vesicles are particularly promising because of lower regulatory complexity and potential for earlier clinical adoption.

    “Among these, non-genetically modified cell therapies and their derived extracellular vesicles (EVs) are particularly promising because of their lower regulatory complexity and potential for earlier clinical adoption (Wang et al., 2021; Bahmani and Ullah, 2022; Thom and Cronin, 2024).”
    Quote in the paperNot a substantial claim3 of 3 sources checked
    • cites Wang et al., 2021 source

      The Biological challenges section (page unavailable) describes non-genetically modified cells as a potentially useful alternative to genetic modification in clinical settings. The Regulatory challenges section (page unavailable) discusses approval barriers for cell therapies generally, but does not say that non-genetically modified therapies or their extracellular vesicles have lower regulatory complexity or could be adopted earlier. The retrieved passages do not address extracellular vesicles. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites Bahmani and Ullah, 2022 source

      The Introduction and §2.3 (page unavailable) describe EVs as promising alternatives to cell therapies, citing therapeutic and safety advantages. They do not distinguish non-genetically modified therapies or attribute their promise to lower regulatory complexity or earlier clinical adoption. The Introduction and §5 instead note hurdles to clinical translation. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites Thom and Cronin, 2024 source

      In “Regulating Novel Cellular Therapies” (page unavailable), the paper says genetically modified cells face additional directives, supporting a narrower point about regulatory burden. “The ATMP Bottleneck” discusses barriers to bringing cell therapies to market, but the paper does not establish that non-genetically modified therapies will be adopted earlier or address their derived extracellular vesicles. (LLM, conf=0.82)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Interpretationcitation

    POC manufacturing is especially suited to autologous therapies by enabling onsite production, reducing transportation time, simplifying logistics, and shortening the vein-to-vein interval.

    “Consequently, POC manufacturing is especially suited to these modalities by enabling onsite production within or near the clinical setting. This arrangement significantly reduces transportation time, simplifies logistics, and shortens the overall vein-to-vein interval (Harrison et al., 2017), which is critical for preserving cell viability and therapeutic potency.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Harrison et al., 2017 source
    • Rests on an assumption: Autologous cell therapies often possess short therapeutic windows and limited cryostability.

  • Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

    Premisecitation

    Establishing harmonized SOPs across sites, adopting digital batch records with centralized data monitoring, and enabling remote QA oversight could mitigate risks while ensuring consistent quality standards across multiple clinical settings.

    “Establishing harmonized SOPs across sites, adopting digital batch records with centralized data monitoring, and enabling remote QA oversight, such as cloud-based audits or centralized review of production and release data, could mitigate these risks while ensuring consistent quality standards across multiple clinical settings (Harrison et al., 2018; Harrison et al., 2017).”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites Harrison et al., 2018 source

      The ‘Decentralisation of QC’ section proposes a central QC hub receiving material or data from local sites, and the ‘Conclusions and forward-looking statement’ identifies site-to-site comparability as a goal. The cited passages do not propose harmonized SOPs, digital batch records, centralized data monitoring, or remote QA audits, nor do they establish that these measures would ensure consistent quality. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites Harrison et al., 2017 source

      In “Systems and technical security” (page unavailable), the paper calls for comparable quality-management systems and consistent standards across sites, and discusses integrated systems that communicate across sites to support oversight. In “Perspectives” (page unavailable), it describes collecting and logging network data. Our copy does not specify harmonized SOPs, digital batch records, remote QA, cloud-based audits, or centralized review of production and release data. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Centralized manufacturing facilities typically maintain dedicated QA departments and well-established SOPs, whereas decentralized POC sites may lack extensive experience implementing full GMP-compliant QA systems, increasing the risk of inconsistent product quality or regulatory non-compliance.

    “Centralized manufacturing facilities typically maintain dedicated QA departments and well-established SOPs, whereas decentralized POC sites may lack extensive experience implementing full GMP-compliant QA systems, increasing the risk of inconsistent product quality or regulatory non-compliance (Shah et al., 2023).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Shah et al., 2023 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    In cell- and EV-based therapies, maintaining strict QC is critical to ensuring safety, consistency, and therapeutic efficacy.

    “In cell- and EV-based therapies, where the “process is the product,” maintaining strict quality control (QC) is critical to ensuring safety, consistency, and therapeutic efficacy (Rohde et al., 2019).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Rohde et al., 2019 source

  • May combine two claims.

    Premisecitation

    The Tissue Factory, an automated isolator-based platform, successfully manufactured multi-layered skeletal myoblast sheets, expanded human articular chondrocytes, and cultured human iPSCs across multiple passages without microbial contamination, demonstrating robust performance comparable to manual operations while minimizing operator intervention and contamination risks.

    “This system successfully manufactured multi-layered skeletal myoblast sheets, expanded human articular chondrocytes, and cultured human iPSCs across multiple passages without microbial contamination, demonstrating robust performance comparable to manual operations while minimizing operator intervention and contamination risks.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Kikuchi et al., 2018 source

  • May combine two claims.

    Premisecitation

    Emerging automated, closed-system platforms offer promising alternatives by minimizing human handling, reducing contamination risks, and increasing batch-to-batch consistency.

    “Emerging automated, closed-system platforms—such as robotic cell culture systems and automated filling units—offer promising alternatives by minimizing human handling, reducing contamination risks, and increasing batch-to-batch consistency (Gupta and Shaz, 2025; Palani et al., 2023; Trainor et al., 2023).”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites Gupta and Shaz, 2025 source

      The Discussion (page unavailable) says automated platforms are increasingly used to streamline CAR T-cell production and may offer an opportunity to standardize manufacturing. It also says variability in protocols and product characteristics persists. The paper does not attribute reduced human handling, lower contamination risk, or greater batch-to-batch consistency to these platforms, and does not identify robotic cell culture systems or automated filling units. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites Palani et al., 2023 source
    • cites Trainor et al., 2023 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Centralized manufacturing remains the dominant approach for allogeneic therapies due to economies of scale and well-established GMP infrastructure.

    “Centralized manufacturing remains the dominant approach for such therapies due to its economies of scale and well-established GMP infrastructure (ten Ham et al., 2020).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites ten Ham et al., 2020 source

      The Discussion (page unavailable) says higher production volume may reduce facility costs and that sharing GMP facilities can spread costs and risks. It does not establish that centralized manufacturing is the dominant approach for allogeneic therapies, or that established GMP infrastructure explains such dominance. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • Rests on an assumption: Allogeneic cell and EV therapies can be manufactured at scale, cryopreserved, and distributed as off-the-shelf therapeutics.

  • May combine two claims.

    Premisecitation

    Autologous cell therapies are typically non-genetically modified, patient-specific, and manufactured in small batches.

    “Autologous cell therapies, including autologous chondrocytes, BMSCs, ADSCs, and immune cell products such as CIK cells and DCs, are typically non-genetically modified, patient-specific, and manufactured in small batches (Marlovits et al., 2006; Wermke et al., 2025).”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites Marlovits et al., 2006 source
    • cites Wermke et al., 2025 source

      The Results (Manufacturing characteristics of TCR T drug product; page unavailable) describe a product made from patients’ own cells and report individual patient product characteristics, supporting the patient-specific aspect. The Methods (Manufacturing of IMA203 products; page unavailable) explicitly state that the T cells are genetically modified, contrary to the non-genetically-modified description. Neither section establishes that autologous cell therapies generally are manufactured in small batches. (LLM, conf=0.87)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The limulus amebocyte lysate (LAL) assay remains the gold standard for endotoxin detection and must be validated for use with each product type and formulation.

    “The limulus amebocyte lysate (LAL) assay remains the gold standard for endotoxin detection and must be validated for use with each product type and formulation (Gorman, 2020).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Gorman, 2020 source

      The Introduction (page unavailable) calls LAL the primary method for endotoxin testing in North America and Europe, supporting its established role but not an unqualified global ‘gold standard’ designation. The section on replacing biomedical horseshoe crab use discusses validation requirements for the alternative rFC test, not a requirement to validate LAL for each product type and formulation. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In IVF, fully enclosed isolator systems significantly improved embryo development to the blastocyst stage, yielding higher cell numbers and accelerated growth compared to conventional open-fronted laminar flow hoods, resulting in increased pregnancy and implantation rates.

    “For example, in reproductive medicine, the implementation of fully enclosed isolator systems for in vitro fertilization (IVF) has significantly improved embryo development to the blastocyst stage, yielding higher cell numbers and accelerated growth compared to conventional open-fronted laminar flow hoods, ultimately resulting in increased pregnancy and implantation rates (Hyslop et al., 2012).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Hyslop et al., 2012 source

  • May combine two claims.

    Interpretationreasoning

    Integration of isolator-based systems into POC models has potential to democratize access to cell and EV therapies by lowering barriers to clinical-grade production and enabling safer, more efficient delivery at the patient's bedside.

    “Their integration into POC models has the potential to democratize access to cell and EV therapies by lowering barriers to clinical-grade production and enabling safer, more efficient delivery at the patient’s bedside.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisereasoning

    Compared to RABS, isolators provide a fully sealed workspace with integrated decontamination and do not require installation within high-grade cleanroom environments.

    “Compared to restricted access barrier systems (RABS), which offer partial separation and rely on the background cleanroom for contamination control, isolators provide a fully sealed workspace with integrated decontamination and do not require installation within high-grade cleanroom environments.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Direct fluorescent staining and membrane filtration approaches, as in ScanRDI, enable near real-time detection by capturing microorganisms on a membrane, staining with nucleic acid-binding fluorophores, and enumerating via laser scanning cytometry, reducing detection time to less than 3 h depending on bioburden levels.

    “Alternatively, direct fluorescent staining and membrane filtration approaches, as employed in systems like ScanRDI, enable near real-time detection by capturing microorganisms on a membrane, staining with nucleic acid-binding fluorophores, and enumerating them via laser scanning cytometry, reducing detection time to less than 3 h depending on bioburden levels (Smith et al., 2010; Mohammadi et al.,”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Smith et al., 2010
    • cites Mohammadi et al., 2023 source

  • Classified as probably not a substantial claim.

    Premisecitation

    Expanded access programs provide a regulatory mechanism for compassionate use of investigational therapies in patients lacking alternative treatment options.

    “In parallel, expanded access programs (EAPs) provide a regulatory mechanism for compassionate use of investigational therapies in patients lacking alternative treatment options (CellTrials, 2024).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites CellTrials, 2024

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

    Interpretationnone given

    POC manufacturing, supported by isolator technology and automation, offers a promising pathway to making advanced therapies more accessible while maintaining the stringent standards necessary for clinical success.

    “POC manufacturing, supported by isolator technology and automation, offers a promising pathway to making advanced therapies more accessible while maintaining the stringent standards necessary for clinical success.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Together, centralized cloud-based MES/eBR, centralized QA oversight, and standardized digital SOPs directly address challenges of standardization and centralized data monitoring, facilitating robust quality assurance across diverse clinical manufacturing settings.

    “Together, these approaches directly address the challenges of standardization and centralized data monitoring, facilitating robust quality assurance across diverse clinical manufacturing settings.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Implementation of centralized cloud-based MES and eBR platforms enables real-time data collection, monitoring, and cross-site analysis, ensuring consistent process parameters, environmental monitoring, and product release criteria across decentralized sites.
    • Rests on an assumption: Centralized QA oversight structures can review and harmonize batch release decisions, while standardized digital SOPs further enforce procedural uniformity.

  • Probably not a substantial claim: may not pass S4 (based).

    Interpretationreasoning

    By combining isolator-based closed-system manufacturing with in-hospital QC testing, POC models can ensure timely release of safe, GMP-compliant cell and EV products.

    “By combining isolator-based closed-system manufacturing with in-hospital QC testing, POC models can ensure timely release of safe, GMP-compliant cell and EV products.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisenone given

    Isolators are completely closed systems that maintain asepsis independent of the surrounding environment, unlike BSCs.

    “Unlike biological safety cabinets (BSCs), which provide open-front airflow protection within classified cleanrooms, isolators are completely closed systems that maintain asepsis independent of the surrounding environment.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Isolator-based systems are sealed containment devices that physically separate operators from the manufacturing environment, thereby maintaining aseptic conditions.

    “Isolator-based systems are widely employed in the pharmaceutical industry as sealed containment devices designed to physically separate operators from the manufacturing environment, thereby maintaining aseptic conditions (Levitan and Perry, 1968; Akers, 2015; Pharmaceutical Inspection Co-operation Scheme (PIC/S), 2007).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Levitan and Perry, 1968 source
    • cites Akers, 2015
    • cites Pharmaceutical Inspection Co-operation Scheme (PIC/S), 2007

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Premisecitation

    Classification as a medicinal product-particularly as an ATMP-triggers compliance with full PIC/S GMP standards, sterility assurance requirements, and formal product release testing.

    “Conversely, classification as a medicinal product—particularly as an ATMP—triggers compliance with full pharmaceutical inspection convention and co-operation scheme (PIC/S) GMP standards, sterility assurance requirements (Pharmaceutical Inspection Co-operation Scheme (PIC/S), 2023), and formal product release testing (Pharmaceutical Inspection Co-operation Scheme (PIC/S), 2022; Ilic et al., 2012a;”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Pharmaceutical Inspection Co-operation Scheme (PIC/S), 2023

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites Pharmaceutical Inspection Co-operation Scheme (PIC/S), 2022

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites Ilic et al., 2012a

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • Rests on an assumption: Cell-based therapies often straddle the boundary between pharmaceutical products and medical procedures.

  • May combine two claims.

    Interpretationreasoning

    Isolators serve as a cost-effective infrastructure option by lowering cleanroom classification requirements, reducing facility construction and operational costs.

    “Second, they serve as a cost-effective infrastructure option by lowering cleanroom classification requirements, thereby reducing facility construction and operational costs.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    Use of pyrogen-free materials and closed-system fluidics within isolators reduces endotoxin contamination risks.

    “The use of pyrogen-free materials and closed-system fluidics within isolators further reduces endotoxin contamination risks.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Interpretationnone given

    Isolator systems can be easily integrated with automated culture, monitoring, and filling technologies, enhancing process standardization and scalability.

    “Third, isolator systems can be easily integrated with automated culture, monitoring, and filling technologies, enhancing both process standardization and scalability.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    POC manufacturing minimizes transportation risks, reduces time-to-treatment, and may allow administration of fresh, non-cryopreserved products.

    “By enabling on-site manufacturing within or near the clinical setting, POC models minimize transportation risks, reduce time-to-treatment, and may allow for the administration of fresh, non-cryopreserved products.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

    Interpretationreasoning

    Widespread adoption of POC manufacturing for cell and EV therapies will require harmonized regulations, targeted workforce development, standardized operational protocols, and continued innovation in GMP-compatible bioprocessing systems.

    “While automation and isolator-based manufacturing technologies have begun to lower some barriers, widespread adoption of POC manufacturing for cell and EV therapies will require harmonized regulations, targeted workforce development, standardized operational protocols, and continued innovation in GMP-compatible bioprocessing systems.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Regulatory alignment across countries remains inconsistent, complicating international deployment and harmonized practice standards.
    • Rests on an assumption: Limitations in workforce availability and technical expertise remain major barriers to POC manufacturing implementation.
    • Rests on an assumption: Effective operation of POC manufacturing requires multidisciplinary teams proficient in aseptic processing, clinical-grade reagent handling, and QC testing.
    • Rests on an assumption: Operators must be trained to perform or supervise critical processes such as sterility assurance, mycoplasma testing, endotoxin screening, and advanced analytics for cell and EV characterization.
    • Rests on an assumption: The availability of such skilled personnel is often limited, particularly in smaller clinical centers.
    • Rests on an assumption: Maintaining operator proficiency within GMP frameworks introduces significant training and documentation burdens.
    • Rests on an assumption: Infrastructure and automation remain additional constraints on scalability.
    • Rests on an assumption: Isolator-based systems' setup and operation still require stringent environmental controls, validated decontamination procedures, and ongoing maintenance.
    • Rests on an assumption: The availability of isolator systems within clinical centers is often limited by high capital costs, spatial requirements, and maintenance demands, particularly outside large academic hospitals.
    • Rests on an assumption: Emerging automated, closed-system technologies remain costly and are not yet widely adopted in clinical practice.
    • Rests on an assumption: QA and regulatory compliance in decentralized settings pose further challenges.

  • May combine two claims.

    Interpretationreasoning

    Overall, isolator-based POC platforms offer modularity, scalability, and high contamination control, making them enabling technologies for distributed manufacturing of both autologous and selected allogeneic therapies.

    “Overall, isolator-based POC platforms offer modularity, scalability, and a high degree of contamination control, making them enabling technologies for distributed manufacturing of both autologous and selected allogeneic therapies (Figure 1).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Isolator-based closed systems allow gene transduction, cell expansion, and final formulation within a fully contained, GMP-compliant environment, minimizing environmental contamination risks and making onsite production of certain gene-modified therapies technically viable.

    “These closed systems allow critical steps, gene transduction, cell expansion, and final formulation, to be performed within a fully contained, GMP-compliant environment, thereby minimizing environmental contamination risks and making onsite production of certain gene-modified therapies technically viable.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationreasoning

    For small and medium-sized biotech companies or academic institutions aiming to meet GMP standards, isolator-based systems present a practical solution.

    “For small and medium-sized biotech companies or academic institutions aiming to meet GMP standards, isolator-based systems present a practical solution.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    EVs are characterized according to MISEV2018 guidelines; key parameters include size and morphology (30-150 nm) via NTA or TEM, marker profiling including tetraspanins and exclusion of non-EV proteins, and cargo analysis.

    “EVs are characterized according to the MISEV2018 guidelines published by the International Society for Extracellular Vesicles (ISEV) (Théry et al., 2018).”
    • Also stated in: § EV characterization · plain
      “Key parameters include: (1) Size and morphology (typically 30–150 nm) via nanoparticle tracking analysis (NTA) or transmission electron microscopy (TEM). (2) Marker profiling, including tetraspanins (CD63, CD81, CD9) and exclusion of non-EV proteins (e.g., GM130, Calnexin) (3) Cargo analysis, such as protein and RNA content via Western blotting, ELISA, or sequencing.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Théry et al., 2018

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    For MSCs, the ISCT outlines three defining criteria: plastic adherence, expression of surface markers CD105, CD73, CD90 with negative hematopoietic markers, and trilineage differentiation potential.

    “For MSCs, the International Society for Cell and Gene Therapy (ISCT) outlines three defining criteria: (1) plastic adherence under standard culture conditions, (2) expression of surface markers CD105, CD73, and CD90, with negative expression of hematopoietic markers (e.g., CD45, CD34, CD14/CD11b, CD79α/CD19, HLA-DR), and (3) trilineage differentiation potential into osteoblasts, adipocytes, and”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Dominici et al., 2006 source

  • May combine two claims.

    Interpretationreasoning

    POC manufacturing may improve patient accessibility and streamline operational costs.

    “This approach may improve patient accessibility and streamline operational costs.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    In EAP contexts, isolator-based POC enables on-demand preparation of personalized products while ensuring regulatory-required quality standards.

    “In EAP contexts, where rapid provision of investigational therapies is critical for patients without alternatives, isolator-based POC enables on-demand preparation of personalized products while ensuring regulatory-required quality standards, thus bridging operational feasibility and compassionate use regulatory frameworks.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationcitation

    Isolator-based platforms reduce supply chain complexity, enhance sterility assurance, and preserve biological integrity of sensitive ATMPs by enabling the entire workflow within a controlled closed environment at or near the bedside.

    “By enabling the entire workflow—from tissue acquisition and cell processing to final formulation and reinfusion—to be carried out within a controlled, closed environment at or near the patient’s bedside, isolator-based platforms reduce supply chain complexity, enhance sterility assurance, and preserve the biological integrity of sensitive ATMPs (Savry et al., 2014).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Savry et al., 2014 source

  • May combine two claims.

    Interpretationcitation

    In hospitals with high patient throughput, establishing in-house production facilities may offer clinical and operational advantages by ensuring consistent supply, reducing reliance on external CDMOs, and enabling rapid adaptation to local clinical needs.

    “However, in hospitals with high patient throughput, establishing in-house production facilities may offer both clinical and operational advantages by ensuring consistent supply, reducing reliance on external CDMOs, and enabling rapid adaptation to local clinical needs.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Isolators minimize human intervention and environmental exposure, significantly reducing risk of microbial contamination.

    “First, they minimize human intervention and environmental exposure, significantly reducing the risk of microbial contamination.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Isolators operating as Grade A environments within at least Grade D cleanroom backgrounds provide superior sterility assurance and operator safety, reduce facility operational complexity and cost, and enable reproducible GMP-compliant manufacturing of ATMPs at larger scales.

    “Isolators, operating as Grade A environments within at least Grade D cleanroom backgrounds, provide superior sterility assurance and operator safety. They also reduce facility operational complexity and cost, enabling reproducible GMP-compliant manufacturing of ATMPs at larger scales.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Zanini et al., 2020 source

  • May combine two claims.

    Premisecitation

    Isolator-based technologies have revolutionized aseptic processing over the past two decades by separating human operators from the production environment, reducing contamination risks and enabling safe manufacture of heat-labile or sensitive biological products.

    “Indeed, isolator-based technologies have revolutionized aseptic processing over the past two decades by effectively separating human operators from the production environment, thereby dramatically reducing contamination risks and enabling the safe manufacture of heat-labile or sensitive biological products (Kokubo et al., 2016).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Kokubo et al., 2016 source
39 of 39

  • The paper relies on this without support.

    Hospitals and clinics present inherent risks of contamination due to high microbial burden and non-sterile environments.

    “Nonetheless, hospitals and clinics present inherent risks of contamination due to their high microbial burden and non-sterile environments.”

  • The paper relies on this without support.

    ATMPs cannot undergo terminal sterilization.

    “Since ATMPs cannot undergo terminal sterilization, rigorous aseptic processing and comprehensive quality control are essential (Harrison et al., 2017).”

  • The paper relies on this without support.

    Autologous cell therapies often possess short therapeutic windows and limited cryostability.

    “These therapies often possess short therapeutic windows and limited cryostability, making fresh, on-demand production particularly advantageous.”

  • The paper relies on this without support.

    Allogeneic cell and EV therapies can be manufactured at scale, cryopreserved, and distributed as off-the-shelf therapeutics.

    “These products can be manufactured at scale, cryopreserved, and distributed as off-the-shelf therapeutics.”

  • The paper relies on this without support.

    Sterility is a mandatory release criterion for all injectable ATMPs.

    “Sterility is a mandatory release criterion for all injectable ATMPs.”

  • The paper relies on this without support.

    Traditional compendial sterility testing requires a 14-day incubation period.

    “Traditionally, compendial sterility testing requires a 14-day incubation period, delaying product release and posing logistical challenges for fresh, non-cryopreserved therapies.”

  • The paper relies on this without support.

    Endotoxins are lipopolysaccharide components of Gram-negative bacteria that can trigger severe immune responses if administered intravenously.

    “Endotoxins are lipopolysaccharide (LPS) components of Gram-negative bacteria that can trigger severe immune responses if administered intravenously.”

  • The paper relies on this without support.

    Cell-based therapies often straddle the boundary between pharmaceutical products and medical procedures.

    “Cell-based therapies often straddle the boundary between pharmaceutical products and medical procedures, a classification with substantial regulatory implications.”

  • The paper relies on this without support.

    Within hospital-based POC manufacturing, positive pressure isolators are most commonly employed.

    “Within hospital-based POC manufacturing, positive pressure isolators are most commonly employed.”

  • The paper relies on this without support.

    Regulatory ambiguity, workforce training limitations, and quality assurance gaps remain in decentralized settings.

    “Despite these advantages, challenges remain, including regulatory ambiguity, workforce training limitations, and quality assurance gaps in decentralized settings.”

  • The paper relies on this without support.

    HE typically focuses on treatments prepared and used within the same hospital.

    “While HE typically focuses on treatments prepared and used within the same hospital”

  • The paper relies on this without support.

    Regulatory alignment across countries remains inconsistent, complicating international deployment and harmonized practice standards.

    “However, regulatory alignment across countries remains inconsistent, complicating international deployment and harmonized practice standards.”

  • The paper relies on this without support.

    Limitations in workforce availability and technical expertise remain major barriers to POC manufacturing implementation.

    “Beyond regulatory ambiguity, limitations in workforce availability and technical expertise remain major barriers to POC manufacturing implementation.”

  • The paper relies on this without support.

    Effective operation of POC manufacturing requires multidisciplinary teams proficient in aseptic processing, clinical-grade reagent handling, and QC testing.

    “Effective operation requires multidisciplinary teams proficient in aseptic processing, clinical-grade reagent handling, and QC testing.”

  • The paper relies on this without support.

    Operators must be trained to perform or supervise critical processes such as sterility assurance, mycoplasma testing, endotoxin screening, and advanced analytics for cell and EV characterization.

    “Operators must be trained to perform or supervise critical processes such as sterility assurance, mycoplasma testing, endotoxin screening, and advanced analytics for cell and EV characterization.”

  • The paper relies on this without support.

    The availability of such skilled personnel is often limited, particularly in smaller clinical centers.

    “However, the availability of such skilled personnel is often limited, particularly in smaller clinical centers”

  • The paper relies on this without support.

    Maintaining operator proficiency within GMP frameworks introduces significant training and documentation burdens.

    “maintaining operator proficiency within GMP frameworks introduces significant training and documentation burdens.”

  • The paper relies on this without support.

    Implementation of centralized cloud-based MES and eBR platforms enables real-time data collection, monitoring, and cross-site analysis, ensuring consistent process parameters, environmental monitoring, and product release criteria across decentralized sites.

    “These digital systems enable real-time data collection, monitoring, and cross-site analysis, ensuring consistent process parameters, environmental monitoring, and product release criteria across decentralized sites.”

  • The paper relies on this without support.

    Centralized QA oversight structures can review and harmonize batch release decisions, while standardized digital SOPs further enforce procedural uniformity.

    “Additionally, centralized quality assurance (QA) oversight structures can review and harmonize batch release decisions, while standardized digital standard operating procedures (SOPs) further enforce procedural uniformity.”

  • The paper relies on this without support.

    Infrastructure and automation remain additional constraints on scalability.

    “Infrastructure and automation remain additional constraints on scalability.”

  • The paper relies on this without support.

    Isolator-based systems' setup and operation still require stringent environmental controls, validated decontamination procedures, and ongoing maintenance.

    “While isolator-based systems reduce reliance on traditional cleanrooms, their setup and operation still require stringent environmental controls, validated decontamination procedures, and ongoing maintenance.”

  • The paper relies on this without support.

    The availability of isolator systems within clinical centers is often limited by high capital costs, spatial requirements, and maintenance demands, particularly outside large academic hospitals.

    “Furthermore, the availability of isolator systems within clinical centers is often limited by high capital costs, spatial requirements, and maintenance demands, particularly outside large academic hospitals.”

  • The paper relies on this without support.

    Emerging automated, closed-system technologies remain costly and are not yet widely adopted in clinical practice.

    “However, these technologies remain costly and are not yet widely adopted in clinical practice.”

  • The paper relies on this without support.

    QA and regulatory compliance in decentralized settings pose further challenges.

    “QA and regulatory compliance in decentralized settings pose further challenges.”
24 of 24

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Conflicting background-room requirements for isolators

    Minor

    The paper says isolators can provide an ISO Class 5 environment in non-classified hospital rooms, but later describes them as operating within at least Grade D cleanroom backgrounds. It is unclear whether a classified background room is required for the proposed point-of-care setup.

1 of 1

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. 2023, Medicines EDftQo, healthcare. european pharmacopoeia
  2. Food, 1997, 21 CFR Part 11: electronic records; electronic signatures
  3. 1994, ISO 10648-2: containment enclosures — Part 2: classification according to leakage tightness and associated checking methods
  4. 2004, ISO 14644-7: cleanrooms and associated controlled environments — Part 7: separative devices (clean air hoods, gloveboxes, isolators and mini-environments)
  5. 2007, PI 014-3: isolators used for aseptic processing and sterility testing
  6. 2022, PIC/S GMP Annex 1: manufacture of sterile medicinal products
  7. 2022, PIC/S GMP annex 2A: manufacture of advanced therapy medicinal products (ATMP) for human Use
  8. 2023, PIC/S Guide to Good manufacturing practice for medicinal products (Part I)

Cited by

Sorted by citations

Related

Authors
Chiu, Y.-S., Wang, K.-L., & Wu, K.-L.
Affiliations
  • Fu Jen Catholic University (TW)
  • I-Shou University (TW)
Corresponding author
Chiu, Yu-Sung
ORCID
Chiu, Yu-Sung
Venue
Frontiers in Bioengineering and Biotechnology
Publisher
Frontiers Media SA
Published
2025-09-03
Volume
13
Pages
1644318-1644318
ISSN
2296-4185 (ISSN-L)
DOI
10.3389/fbioe.2025.1644318
PMC
PMC12440961
OpenAlex
W4413961666
Semantic Scholar
b938d03e1dd2b4d0d42a8b82c3eac68f923b3f97
Cited by
17
References
101
Citations by year
2026: 16 · 2025: 1
FWCI
1.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Physiology › Biomedical Ethics and Regulation
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
point-of-care manufacturing, extracellular vesicle therapy, GMP compliance, distributed manufacturing, quality control, regulatory framework, contamination risk reduction, personalized medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-28.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-28.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review